Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05034536 · ClinicalTrials.gov registry record · Phase 2
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
A Phase 2 study of Metastatic Melanoma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05034536 is a Phase 2 study of Metastatic Melanoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 36 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05034536, a Phase 2 study of Metastatic Melanoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Nivolumab
- DRUG Relatlimab
- DRUG Infliximab
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05034536
The ClinicalTrials.gov registry entry for NCT05034536 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (57% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05034536 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05034536 about?
NCT05034536 is a clinical study titled "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma". The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.
What is the current status of trial NCT05034536?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-02-07. Estimated completion is 2027-12-31.
What conditions does trial NCT05034536 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
What interventions are being tested in trial NCT05034536?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Nivolumab (DRUG), Relatlimab (DRUG), Infliximab (DRUG).
Who is sponsoring clinical trial NCT05034536?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05034536 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.